Biotech Values

[genisi]

one of the postulated MOAs of ribavirin, which is that it boosts the mutation rate of HCV.

If you check the literature, I think you'll find that the mutagenic effect of ribavirin was seen in vitro studies using much higher doses than those in use in human therapy. The part on ribavirin's MoA from the NEJM paper you cited by Hézode et al is:

ribavirin has been shown to prevent viral breakthrough during, and relapse after, the treatment period by significantly accelerating the second slope of viral-RNA decrease in patients who have a response to the antiviral effect of peginterferon alfa.